Fig. 9
From: Identification of an RNA binding protein-related gene signature in hepatocellular carcinoma patients
The expression level of SMG5, EZH2, FBLL1, ZNF239, IGF2BP3 in the Oncomine database and The Human Protein Atlas. a Expression level of SMG5 in HCC and Liver. b Expression level of EZH2 in HCC and Liver. c Expression level of ZNF239 in HCC and Liver. d Expression level of IGF2BP3 in HCC and Liver. e Immunohistochemistry results of EZH2 in HCC (Staining: Medium; Intensity: Moderate; Quantity: 75–25%; Location: Nuclear) and in normal tissue (Staining: Not detected; Intensity: Negative; Quantity: None; Location: None). f Immunohistochemistry results of IGF2BP3 in HCC (Staining: high; Intensity: strong; Quantity: 75–25%; Location: Cytoplasmic/membranous) and in normal tissue (Staining: Not detected; Intensity: Negative; Quantity: None; Location: None). g Immunohistochemistry results of ZNF239 in HCC (Staining: Not detected; Intensity: Negative; Quantity: None; Location: None) and in normal tissue (Staining: Not detected; Intensity: Negative; Quantity: None; Location: None). h Prognostic value of SMG5. i Prognostic value of FBLL1. j Prognostic value of EZH2. k Prognostic value of ZNF293. l Prognostic value of IGF2BP3